Discontinued — last reported Q4 '25
Year-over-year, this metric grew by 473.9%, from $111.00M to $637.00M.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $64.00M | $64.00M | $64.00M | $589.00M | $0.00 | $0.00 | $111.00M | $0.00 | $0.00 | $637.00M |
| QoQ Change | — | +0.0% | +0.0% | +820.3% | -100.0% | — | — | -100.0% | — | — |
| YoY Change | — | — | — | — | -100.0% | -100.0% | — | — | — | +473.9% |